Related Experiment Video
Updated: Jan 6, 2026

One-day Workflow Scheme for Bacterial Pathogen Detection and Antimicrobial Resistance Testing from Blood Cultures
Published on: July 9, 2012
Exploring heterogeneity in antibiotic choices for bloodstream infections caused by AmpC-producing enterobacterales:
Gianpiero Tebano1,2, Caterina Campoli3, Marianna Meschiari4
1Department of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum, University of Bologna, Bologna, Italy. gianpiero.tebano@unibo.it.
Purpose:
The treatment of bloodstream infections (BSIs) caused by AmpC-producing Enterobacterales (AmpC-E) remains controversial, due to limited clinical evidence and variable resistance profiles. Inappropriate antibiotic choices can induce ampC-encoding gene overexpression, leading to increased risk of therapeutic failure. This study aims to explore the current prescribing preferences among infectious disease (ID) physicians, in complex clinical scenarios involving BSIs caused by AmpC-E.
Methods:
A web-based case-vignette survey was conducted among a purposive sample of senior ID physicians from 10 ID units in Emilia-Romagna Region, northern Italy. Participants responded to 31 vignettes simulating BSIs caused by Enterobacter cloacae (wild-type or derepressed phenotype) or Serratia marcescens (wild-type phenotype), across varied clinical settings. For each scenario, participants selected their preferred antibiotic regimen.
Results:
Forty-two ID physicians were invited to participate. Cefepime (48.4%) and meropenem (29.0%) were the most prescribed agents, followed by piperacillin-tazobactam (16.1%) and third-generation cephalosporins (3GC) (6.5%). Cefepime was preferred in milder cases, while meropenem in severe infections, particularly with high inoculum or incomplete source control. Considerable heterogeneity in treatment choices was observed, especially for S. marcescens and E. cloacae with wild-type phenotypes. Agreement among clinicians was highest for intensive care admitted patients. Combination therapies were infrequently proposed (8.8% overall), primarily in the setting of intra-abdominal infections with incomplete source control or ventilator-associated pneumonia.
Conclusion:
This study highlights significant variability in the treatment of AmpC-E BSIs among ID physicians, reflecting clinical uncertainty and lack of high-quality evidence. Further research and updated, context-specific guidelines are needed to harmonize practice and promote optimal antibiotic stewardship.
More Related Videos
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
08:58Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Related Concept Videos
Antibiotic Selection
Antimicrobial Effectiveness
Development of Antibiotic Resistance
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Healthcare Associated Infections I: Iatrogenic, Exogenic and Endogenic
HAIs significantly increase the cost of health care. Extended stays in healthcare institutions, increased disability, increased costs of medications, including specialized antibiotics, and prolonged recovery times add to the patient's expenses and the healthcare institution and funding bodies.
Combined Effects of Drugs: Synergism
Such synergistic combinations...